Cardiovascular Drugs Market (By Drug Type: Antihypertensive, Anticoagulants, Antihyperlipidemic, Antiplatelet Drugs, Others; By Disease Indication: Hypertension, Coronary Artery Disease, Hyperlipidaemia, Arrhythmia, Others; By Route of Administration: Oral, Parenteral, Others; By Drug Classification; By Mode of Purchase; By End Users)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Cardiovascular Drugs market size was estimated at USD 155.6  billion in 2021 and is expected to surpass around USD 231.7  billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 4.52% during the forecast period 2022 to 2030.

Key Takeaways:

• By type, anticoagulants segment was reached revenue share of about 43% in 2021.
• The antihyperlipidemic drug type segment exhibited 15.6% revenue share in 2021.
• North America region has garnered revenue share of around 38% in 2021.

 Cardiovascular drugs refers to prescription drugs and medicines for diseases relating to the structure and function of the heart and blood vessels and diseases such as heart failure, coronary artery disease, high cholesterol, blood clots, circulation disorders, and others. These diseases are associated with circulatory system and heart. The cardiovascular diseases such as rheumatic heart disease, hypertensive heart disease, inflammatory heart disease, ischemic heart disease, and cerebrovascular heart disease. High blood pressure causes hypertensive heart disease. Key concerns related to hypertensive heart disease are hypertrophy, heart failure, angina, and coronary heart disease. Brain blood vessels get affected by the cerebrovascular disease. Cerebrovascular disease common types are a stroke, vascular dementia, transient ischemic attack, and subarachnoid haemorrhage.

Report Scope of the Cardiovascular Drugs Market

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact analysis:

Cardiovascular diseases (CVDs) comprise disorders and conditions related to circulatory system which include heart and vascular system. Drug classes used to treat cardiovascular indications such as hyperlipidaemia, hypertension are likely to fuel expansion of the global cardiovascular drug market from 2022to 2030.

Trends:

Cardiovascular diseases are one of the leading causes of death worldwide. According to American Heart Association, in 2015, approximately 41.9% of the U.S. population was suffering from some form of cardiovascular disease, it is further estimated that this prevalence is likely to increase to 45% by 2035. Sedentary lifestyle, changing dietary habits and surge in associated risk factors are likely to increase the number of patients with cardiovascular diseases.

According to the Centres for Disease Control and Prevention (CDC) of the U.S., high blood pressure, high cholesterol, and smoking are key risk factors for heart disease. About half of the population of the U.S. (48%) have at least one of these three risk factors. To treat the diseases, key players are investing in to develop new drugs with better efficacy and less side effects.

Drivers:

Increase in number of cardiovascular disease:

As the global population pushes past 7.2billion and more people reach old age, the number of deaths from cardiovascular diseases is on the rise. Cardiovascular diseases, the leading cause of premature death in the world, include heart attacks, strokes, and other circulatory diseases. Due to this, efforts to prevent and treat cardiovascular diseases through medication are on the rise resulting in slower death-rate and increased business for cardiovascular drug market.

Also there is an increase in tobacco use, unhealthy diet and obesity, physical inactivity and harmful use of alcohol resulting in more CVD and need for medication.

Restrains:

Stringent regulations and side-effects of cardiovascular drugs hamper the growth of global cardiovascular drugs market. Moreover, patent expiry of various blockbuster drugs also obstructs the growth of the global cardiovascular drug market. Increasing mergers and acquisitions between drug manufacturing companies and rapid product launches are key trends of the global cardiovascular drugs market.

Regional analysis:

North America dominates the global cardiovascular drugs market. This is due to increased awareness about various heart diseases in the region. The U.S. represents the largest market for cardiovascular drugs followed by Canada in North America. In Europe, Germany, the U.K., Spain, Italy and France holds major share of cardiovascular drug market. However, Asia is expected to show high growth rates in the next five years in global cardiovascular drugs market. This is due to many companies constructing their R&D facilities in the region. Less stringent wages and availability of skilled labour attracts manufacturing companies to invest in Asia. In addition, increasing awareness about heart related problems is also supporting in the growth of cardiovascular drugs market in the region. Japan, China and India are expected to be the fastest growing cardiovascular drug markets in Asia.

Drug Type Insights

On the basis of drug type, the antihypertensive drugs have dominated the segment as it is the most common disorder that people are seen suffering with as a result of the high amount of salt intake and age-related disorders. The increasing stress among the people as a result of work and frustration has also increased its prevalence in the society.

These drugs form a habit among the consumers which makes them purchase these drugs again and again, thus boosting the market size over the period of time. The prevalence of cholesterol has increased the use of antihyperlipidemic drugs which shows a rapid growth. Anticoagulants forms the next segment which too records a considerable growth as a result of increasing prevalence of cardiac arrest among the people.

Disease Indication Insights

On the basis of disease indication, hypertension has dominated the segment as it is the most common disease that people are seen suffering with as a result of the high work pressure among the youngsters and the age-related disorders which are caused in the geriatric population. Lack of physical activity also gives rise to a number of diseases. Higher intake of fast foods and salt has increased the prevalence of hypertension.

Heavy consumption of alcohol too leads to the causation of this cardiovascular disorder which is commonly seen among the people. Arrhythmias and hyperlipidemia form the next segment as a result of the sedentary lifestyle practices of the people and faulty lifestyle practices. CAD forms the next segment which also contributes considerably to the growth of the market.

End Users Insights

On the basis of end user, the hospital pharmacies record the highest growth as a result of the rapid demand and supply of cardiovascular drugs seen due to the easy availability of rare and commonly used drugs. The emergency cardiovascular drugs are easily available in the hospital pharmacies which are very costly and find their place in the hospitals only.

Retails stores form the next segment which shows the fastest growth as a result of its easy accessibility to the common people. Online stores too show a considerable growth with the increasing trend of online shopping. The demand for contactless delivery services of drugs has boosted the demand for cardiovascular drugs through online stores which also provides a wide range of lucrative discounts and offers to the consumers in order to attract them. The availability of a ready comparison between the other available drugs also helps the consumer to make a suitable choice of drugs.

Regional analysis:

North America dominates the global cardiovascular drugs market. This is due to increased awareness about various heart diseases in the region. The U.S. represents the largest market for cardiovascular drugs followed by Canada in North America. In Europe, Germany, the U.K., Spain, Italy and France holds major share of cardiovascular drug market. However, Asia is expected to show high growth rates in the next five years in global cardiovascular drugs market. This is due to many companies constructing their R&D facilities in the region. Less stringent wages and availability of skilled labour attracts manufacturing companies to invest in Asia. In addition, increasing awareness about heart related problems is also supporting in the growth of cardiovascular drugs market in the region. Japan, China and India are expected to be the fastest growing cardiovascular drug markets in Asia.

Some of the prominent players in the Cardiovascular Drugs Market include:

• Bristol-Myers Squibb Company
• Bayer AG
• Pfizer Inc.
• Janssen Pharmaceuticals, Inc.
• Novartis AG
• Merck & Co.
• AstraZeneca
• Sanofi
• Gilead Sciences, Inc.
• F. Hoffmann-La Roche 

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Cardiovascular Drugs market

By Drug Type

• Antihypertensive
• Anticoagulants
• Antihyperlipidemic
• Antiplatelet Drugs
• Others

By Disease Indication

• Hypertension
• Coronary Artery Disease
• Hyperlipidaemia
• Arrhythmia
• Others

By Route of Administration

• Oral
• Parenteral
• Others

By Drug Classification

• Branded Drugs
• Generic Drugs

By Mode of Purchase

• Prescription-Based Drugs
• Over-The-Counter Drugs

By End Users

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Others

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Points Covered in Cardiovascular Drugs Market Study:

• Growth of Cardiovascular Drugs in 2022
• Market Estimates and Forecasts (2017-2030)
•  Brand Share and Market Share Analysis
•  Key Drivers and Restraints Shaping Market Growth
•  Segment-wise, Country-wise, and Region-wise Analysis
•  Competition Mapping and Benchmarking
•  Recommendation on Key Winning Strategies
•  COVID-19 Impact on Demand for Cardiovascular Drugs and How to Navigate
•  Key Product Innovations and Regulatory Climate
•  Cardiovascular Drugs Consumption Analysis
•  Cardiovascular Drugs Production Analysis
•  Cardiovascular Drugs and Management